How ketamine can quickly reverse stress-related loss of pleasure
A synaptic substrate for ketamine-mediated amelioration of stress-induced anhedonia
This work looks at how a single low dose of ketamine can rapidly restore pleasure and motivation for people with stress-related depression.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11129906 on NIH RePORTER |
What this research studies
From a patient's perspective, researchers are examining the brain circuits and synapses that let ketamine relieve the loss of pleasure caused by chronic stress. They use laboratory models of stress-linked depression to see how ketamine activates AMPA receptors and promotes formation of new synaptic connections. The team measures behavior, images synapses, and manipulates specific neurons and receptors to map the precise steps involved. The aim is to identify targets that could lead to faster-acting treatments for people whose depression does not respond to standard antidepressants.
Who could benefit from this research
Good fit: People with major depressive disorder—especially those with treatment-resistant depression and prominent anhedonia—are the most relevant group for this line of research.
Not a fit: People without depression or whose symptoms do not include loss of pleasure are unlikely to gain direct benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could point to faster-acting antidepressant approaches that reduce anhedonia in people with treatment-resistant depression.
How similar studies have performed: Clinical trials have shown single low doses of ketamine can rapidly reduce depressive symptoms and anhedonia in many patients, but the detailed synaptic mechanisms remain incompletely tested.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Pignatelli, Marco — Washington University
- Study coordinator: Pignatelli, Marco
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.